Work

Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.11024

Authors: Bella Kaufman, Ronnie Shapira-Frommer, Rita K. Schmutzler, M. William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Karin Bowen, Anitra Fielding, Susan M. Domchek

Institutions: Sheba Medical Center, Tel Aviv University, Cedars-Sinai Medical Center, Prince of Wales Hospital, Vall d'Hebron Hospital Universitari, Peter MacCallum Cancer Centre, AstraZeneca (United Kingdom), Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2409685183

Cites:

Cited by: 28

Related to: 10